Neurogene Inc.

NGNE Healthcare Biotechnology

Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00. In the quarter to June 2026, EPS fell 45.7%, free cash flow fell 23.0% and total debt fell 66.7%, each against the same quarter a year earlier.

23.27 0.68 −2.84%
Market cap
$479.3M
P/E
0.0×
Fwd P/E
−4.5×
Dividend yield
—
F-score
n/a
Altman Z
8.68
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
228.91 246.75 271.77 270.52
Total non-current assets
15.45 16.39 16.83 17.31
Total Assets
244.36 263.14 288.60 287.83
Total current liabilities
21.51 18.87 16.41 14.71
Total non-current liabilities
5.73 6.49 7.31 7.58
Total liabilities
27.23 25.36 23.72 22.29
Common Equity (Total)
217.13 237.78 264.89 265.54
Shareholders Equity (Total)
217.13 237.78 264.89 265.54
Total Debt
0.00 0.00 0.01 0.01

Show all line items

In millions of $ except per-share values · columns are period end dates